Related Experiment Videos
Trilineage hematopoietic toxicity associated with valproic acid therapy
K S Bottom1, D M Adams, K P Mann
1Department of Pediatrics, Duke University Medical Center, Durham, North Carolina 27710, U.S.A.
Journal of Pediatric Hematology/Oncology
|January 1, 1997
Summary
Sodium valproate, an anticonvulsant, can cause severe blood disorders. Discontinuing the drug resolved anemia, thrombocytopenia, and coagulopathy in an infant, highlighting potential valproate toxicity.
Area of Science:
- Hematology
- Pharmacology
- Oncology
Background:
- Sodium valproate is a widely used anticonvulsant for refractory epilepsy.
- Previous reports indicate valproate-associated hematopoietic toxicity, including effects on platelets and erythrocytes, and rare bone marrow suppression.
Observation:
- An infant treated with sodium valproate developed severe anemia, thrombocytopenia, coagulopathy, and circulating immature myeloid cells.
- Bone marrow examination revealed approximately 40% abnormal promyelocytes, initially mimicking acute promyelocytic leukemia.
Findings:
- Hematopoietic abnormalities, including anemia and thrombocytopenia, resolved completely after sodium valproate discontinuation.
- The patient's condition improved without antineoplastic therapy, suggesting drug-induced toxicity.
Implications:
- This case expands the known spectrum of hematopoietic toxicity linked to sodium valproate.
- Clinicians should consider sodium valproate toxicity in patients presenting with unexplained hematopoietic abnormalities.
- Early recognition and drug withdrawal are crucial for managing valproate-induced hematologic complications.